Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Dao, Kim-Hien T., Gotlib, Jason, Deininger, Michael M.N., Oh, Stephen T., Cortes, Jorge E., Collins, Robert H., Winton, Elliot F., Parker, Dana R., Lee, Hyunjung, Reister, Anna, Schultz, Savage, Samantha, Stevens, Brockett, Chase, Subbiah, Nan, Press, Richard D., Raess, Philipp W., Cascio, Michael, Dunlap, Jennifer, Chen, Yiyi, Degnin, Catherine, Maxson, Julia E., Tognon, Cristina E., Macey, Tara, Druker, Brian J., Tyner, Jeffrey W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2020
Aiheet:
RAPID COMMUNICATIONS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106977/
https://ncbi.nlm.nih.gov/pubmed/31880950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00895
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia